In January 2025, the FDA approved a migraine drug called Symbravo that achieved pain relief in 68 percent of patients within two hours and sustained that relief in over 80 percent through the following 24 to 48 hours. Developed by Axsome Therapeutics, Symbravo combines two established medications — meloxicam, an anti-inflammatory NSAID, and rizatriptan, a fast-acting triptan — into a single oral tablet. For the roughly 39 million Americans who live with migraine, many of whom have cycled through treatments that either work too slowly or wear off too soon, those numbers represent a genuine shift in what acute treatment can deliver. The headline claim of “80 percent in two hours” deserves some clarification upfront. No currently approved migraine drug achieves 80 percent complete pain freedom at the two-hour mark in clinical trials.
What Symbravo’s MOVEMENT trial actually showed was 68 percent pain relief at two hours and over 80 percent sustained relief through 24 to 48 hours. The distinction matters, but the overall picture is still striking — especially when you consider that 85 percent of patients in the trial did not need rescue medication through the first 24 hours. For anyone who has spent a migraine huddled in a dark room wondering whether their pill is going to kick in before the day is gone, that kind of sustained efficacy is not a technicality. It is the whole point. This article breaks down exactly how Symbravo works, what the clinical trials found, how it compares to other leading migraine treatments, who stands to benefit the most, and what limitations you should know about before talking to your doctor.
Table of Contents
- How Did Symbravo Achieve Pain Relief in 2 Hours for So Many Migraine Patients?
- What the Clinical Trials Actually Found — and Where the Numbers Get Nuanced
- How Symbravo Compares to Other Leading Migraine Treatments
- Who Should Ask Their Doctor About Symbravo — and Who Should Not
- The Limitations of Current Migraine Drug Research and What the Numbers Do Not Tell You
- What the Symbravo Approach Means for Future Migraine Drug Development
- The Evolving Landscape of Brain Health and Migraine Treatment
- Conclusion
- Frequently Asked Questions
How Did Symbravo Achieve Pain Relief in 2 Hours for So Many Migraine Patients?
The key to Symbravo’s performance lies in its dual-mechanism design. Rizatriptan, which has been used as a standalone triptan for years, works by binding to serotonin receptors in the brain to constrict dilated blood vessels and block pain pathways. It acts fast — patients in the MOVEMENT trial reported pain relief beginning within the first hour, with 39 percent achieving relief at that early mark. Meloxicam, the other half of the combination, is a longer-acting NSAID that targets the inflammatory cascade that sustains and worsens migraine pain over time. By pairing a rapid-onset agent with a sustained anti-inflammatory, Symbravo addresses two phases of migraine simultaneously rather than asking one drug to do everything. This is not just a theoretical advantage. In the MOMENTUM trial, which specifically enrolled patients with moderate-to-severe migraine attacks, Symbravo achieved pain freedom at two hours in 23 percent of patients compared to 11 percent on placebo.
Freedom from the most bothersome symptom — whether that was nausea, light sensitivity, or sound sensitivity — reached 39 percent versus 25 percent on placebo. Both results were statistically significant, with P values below .001. For context, achieving pain freedom (not just relief, but the complete absence of pain) in nearly a quarter of severe migraine attacks at the two-hour mark is a meaningful result. Many existing treatments struggle to clear that bar. What made the combination especially interesting to researchers was the sustained effect. Unlike some triptans that provide initial relief only for the migraine to return hours later — a phenomenon neurologists call “headache recurrence” — Symbravo’s inflammatory suppression through meloxicam appeared to help prevent that rebound. The fact that 83 percent of patients remained free of rescue medication through 48 hours suggests the drug was not just masking the pain temporarily but interrupting the migraine process more completely.
What the Clinical Trials Actually Found — and Where the Numbers Get Nuanced
Three major trials formed the backbone of Symbravo’s FDA approval. The MOVEMENT trial established the core efficacy profile in general acute migraine, showing that two-hour pain relief trajectory of 39 percent at one hour, 68 percent at two hours, and over 80 percent sustained through 24 to 48 hours. The MOMENTUM trial focused on the harder-to-treat population of moderate-to-severe attacks, and the INTERCEPT trial examined outcomes when patients took the drug during the mild phase of a migraine, before it had a chance to intensify. In INTERCEPT, pain freedom at two hours reached 32.6 percent versus 16.3 percent on placebo, suggesting a potential benefit to early intervention. However, it is important to understand what “pain relief” means versus “pain freedom” in clinical trial language, because the two are not the same. Pain relief means a reduction from moderate or severe pain to mild or no pain. Pain freedom means the complete absence of headache pain.
The 68 percent figure at two hours from the MOVEMENT trial refers to pain relief, not pain freedom. The pain freedom numbers are lower across all trials, which is standard for migraine research. If you are someone who considers a treatment successful only if it eliminates your migraine entirely within two hours, the realistic expectation for Symbravo is closer to that 23 percent figure from MOMENTUM. That is still better than placebo by a wide margin, but it is not the sweeping cure that a casual reading of the headline might suggest. The other caveat worth noting is that clinical trial populations are carefully selected. Patients with certain cardiovascular conditions, uncontrolled hypertension, or those taking other serotonergic drugs are typically excluded. Real-world performance can differ from trial results, and the early months after a drug’s approval often reveal how the numbers hold up in the broader, messier population of actual patients. None of this diminishes Symbravo’s results, but anyone considering the drug should have a realistic picture rather than one built on conflated statistics.
How Symbravo Compares to Other Leading Migraine Treatments
Symbravo enters a crowded field, and understanding where it fits requires looking at the alternatives. Among oral triptans, eletriptan at 80 milligrams has historically shown the highest two-hour headache response rate at roughly 77 percent, making it the closest competitor in terms of raw speed. Subcutaneous sumatriptan at 6 milligrams — an injection rather than a pill — achieves about 59 percent pain freedom at two hours, with over 90 percent of patients experiencing some improvement by that mark. But injections come with their own barriers, including needle aversion and the impracticality of self-administering during a migraine attack at work or in public. The newer CGRP-class medications offer a different profile. Nurtec ODT, an oral dissolving tablet containing rimegepant, showed 59.3 percent pain relief at two hours versus 43.3 percent on placebo.
Ubrelvy, another oral CGRP antagonist, demonstrated about 60 percent pain relief within two hours. The nasal spray Zavzpret, containing zavegepant, achieved 24 percent pain freedom at two hours but offered relief as early as 15 minutes for some patients, making it appealing for those who need fast onset through a non-oral route. Each of these drugs has distinct advantages depending on a patient’s tolerance profile, how fast they need relief, and whether they have contraindications to triptans or NSAIDs. Where Symbravo distinguishes itself is in the sustained relief metric. While many of these treatments show competitive two-hour numbers, the question of what happens at hours six, twelve, and twenty-four is where migraines reveal their true burden. A drug that provides initial relief but lets the migraine return at midnight is only solving half the problem. Symbravo’s 80-plus percent sustained relief through 24 to 48 hours, paired with the high rate of patients avoiding rescue medication, suggests it may be addressing that durability gap more effectively than monotherapy options.
Who Should Ask Their Doctor About Symbravo — and Who Should Not
The most obvious candidates for Symbravo are patients who have found that triptans alone provide partial or short-lived relief. If you have been prescribed rizatriptan or sumatriptan and found that your migraine comes back hours after the first dose, the addition of meloxicam’s sustained anti-inflammatory action may be exactly what is needed to prevent that rebound. Similarly, patients who get relief from NSAIDs but find it too slow to address the acute intensity of a migraine may benefit from the combination approach. One particularly notable finding from Symbravo’s research is its demonstrated efficacy in patients who were unresponsive to CGRP-class treatments. For the growing number of migraine patients who have tried medications like Nurtec, Ubrelvy, or the injectable CGRP antibodies like Aimovig or Ajovy without adequate results, Symbravo offers a mechanistically different option. This is not a trivial point. CGRP drugs were hailed as a breakthrough when they arrived, and for many patients they have been.
But a significant subset does not respond adequately to CGRP-targeting treatments, and those patients have had limited options beyond cycling through older drug classes. Symbravo fills that gap. On the other hand, Symbravo carries the contraindication profile of both its components. Rizatriptan, as a triptan, is generally not recommended for patients with a history of cardiovascular disease, stroke, or uncontrolled hypertension. Meloxicam, as an NSAID, brings concerns about gastrointestinal bleeding, kidney function, and cardiovascular risk with prolonged or frequent use. Patients who take migraine medications more than ten days per month also need to be cautious about medication overuse headache, which can develop with any acute treatment. Symbravo is approved for acute treatment, not daily prevention, and using it too frequently could paradoxically worsen headache frequency over time.
The Limitations of Current Migraine Drug Research and What the Numbers Do Not Tell You
Clinical trials are designed to measure average outcomes across large populations, and migraine is a notoriously individualized condition. Two patients with identical diagnoses can respond completely differently to the same drug. The 68 percent pain relief rate at two hours means that roughly one in three patients in the MOVEMENT trial did not get meaningful relief in that timeframe. For those individuals, Symbravo is not the answer, and the search for an effective acute treatment continues. This is the nature of migraine pharmacology — no single drug works for everyone, and the process of finding the right treatment often involves structured trial and error. Another limitation is the question of long-term safety data. Symbravo was approved based on its Phase 3 trial program, which is sufficient for FDA evaluation but does not capture the effects of using the drug over years.
Patients with frequent migraines who might take Symbravo multiple times per month will need to weigh the cumulative exposure to both an NSAID and a triptan. Meloxicam, while generally better tolerated than some other NSAIDs, still carries the class warning about cardiovascular and gastrointestinal risks with extended use. Your doctor should be involved in monitoring for these issues, particularly if you have other health conditions that increase your baseline risk. The cost question also looms. New brand-name medications frequently come with high out-of-pocket costs, especially in the first years before generics become available. If your insurance does not cover Symbravo, or imposes step therapy requirements that force you to fail on cheaper alternatives first, access may be a practical barrier regardless of the drug’s clinical merits. This is worth discussing with both your neurologist and your pharmacist before assuming Symbravo will be an easy switch.
What the Symbravo Approach Means for Future Migraine Drug Development
Symbravo’s approval represents something broader than one new pill on the pharmacy shelf. It validates the concept of rational combination therapy in migraine — the idea that pairing two drugs with complementary mechanisms can outperform either one alone. This is not a new concept in medicine (tuberculosis and HIV treatment have relied on combination therapy for decades), but migraine treatment has been slow to adopt it formally.
Most migraine patients who combine medications do so informally, taking a triptan and an NSAID from separate bottles based on their doctor’s advice or their own experimentation. Having an FDA-approved combination that has been tested as a unit, with pharmacokinetics specifically optimized for co-delivery, is a different proposition. The success of this model may encourage further development of combination approaches — perhaps pairing CGRP antagonists with other drug classes, or combining acute and preventive mechanisms in ways that have not yet been tested. For the migraine research community, Symbravo is a proof of concept that the bar for acute treatment can still be raised.
The Evolving Landscape of Brain Health and Migraine Treatment
Migraine is increasingly understood not as a standalone headache disorder but as a neurological condition with implications for long-term brain health. Research has drawn connections between chronic migraine and increased risk of white matter lesions, and some studies have explored potential associations between severe migraine history and cognitive changes later in life.
While the evidence does not establish migraine as a direct cause of dementia, the overlap in affected brain regions and inflammatory pathways means that effective migraine management may carry benefits beyond just controlling pain. For patients and caregivers already navigating the complexities of brain health — whether through personal experience with migraine, family history of neurological conditions, or a broader interest in protecting cognitive function — developments like Symbravo are worth watching. The trajectory of migraine treatment is moving toward faster, more sustained, and more personalized interventions, and each step forward expands the options available to the millions of people who have been underserved by older approaches.
Conclusion
Symbravo represents one of the most meaningful additions to the acute migraine treatment arsenal in recent years. Its combination of rizatriptan for fast-acting relief and meloxicam for sustained anti-inflammatory suppression produced a clinical profile — 68 percent pain relief at two hours, over 80 percent sustained through 24 to 48 hours, and demonstrated efficacy even in CGRP non-responders — that addresses several of the most common frustrations patients have with existing options. The headline figure of “80 percent in two hours” is a slight oversimplification, but the underlying data is genuinely encouraging.
If you experience migraines and your current treatment leaves you with incomplete relief, rebound headaches, or too many days reaching for rescue medication, Symbravo is worth discussing with your neurologist. As with any medication, the decision should account for your full health profile, your treatment history, and the practical realities of cost and access. But for the first time in a while, there is a new option that was designed from the ground up to tackle both the speed and durability problems that have defined acute migraine treatment for decades.
Frequently Asked Questions
Is Symbravo available by prescription now?
Yes. Symbravo received FDA approval on January 30, 2025, for the acute treatment of migraine with or without aura in adults. It is available by prescription, though insurance coverage and formulary status may vary depending on your plan.
Can I take Symbravo if I already take a CGRP medication for migraine prevention?
Symbravo is an acute treatment, meaning it is taken at the onset of a migraine rather than daily. Many patients use a preventive medication alongside a separate acute treatment. However, drug interactions should always be reviewed by your doctor, particularly if you are on other serotonergic medications.
What is the difference between pain relief and pain freedom in migraine trials?
Pain relief means a reduction in pain severity, typically from moderate or severe to mild or no pain. Pain freedom means the complete absence of headache pain. In Symbravo’s MOMENTUM trial, pain freedom at two hours was 23 percent — lower than the pain relief rate but still statistically significant compared to placebo at 11 percent.
Does Symbravo work for people who did not respond to CGRP treatments?
Clinical data showed that Symbravo demonstrated therapeutic efficacy in patients who were unresponsive to CGRP-class treatments. This makes it a potentially important option for patients who have tried drugs like Nurtec, Ubrelvy, or CGRP antibodies without adequate relief.
How does Symbravo compare to taking rizatriptan and an NSAID separately?
While many patients informally combine a triptan and an NSAID, Symbravo was specifically formulated and tested as a combination product with optimized co-delivery. The clinical trial data reflects this specific formulation, and the results may not be directly equivalent to taking the two drugs separately from different bottles.
Are there people who should not take Symbravo?
Patients with cardiovascular disease, a history of stroke, uncontrolled hypertension, or those at risk for gastrointestinal bleeding should discuss risks carefully with their doctor. Symbravo carries the contraindication profiles of both triptans and NSAIDs. It is also not intended for daily use, and frequent use could contribute to medication overuse headache.
